DeepScribe vs Noom
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco ambient AI scribe using smartphone to listen to patient visits; generates structured EHR notes within minutes, customizable to each physician's documentation style.
About
DeepScribe is a San Francisco-based ambient AI medical scribe company that uses machine learning to listen to physician-patient conversations and automatically generate complete, structured clinical documentation without physician dictation or manual entry. The platform runs on a smartphone placed in the exam room, processes the conversation to identify medically relevant information, and presents a complete draft note in the EHR within minutes of the visit ending. DeepScribe differentiates through its customization capabilities — physicians can train the AI to match their personal documentation style, preferred note templates, and specialty-specific terminology, making the output immediately publishable with minimal editing. The company serves primary care, specialty, and urgent care physicians as well as telehealth providers. Founded in 2017, DeepScribe raised over $30M from investors including Kaiser Permanente Ventures, Greycroft, and SignalFire. The company has demonstrated significant time savings for clinicians and reductions in EHR-related stress. It competes with Suki AI, Nuance DAX, and Freed AI in the ambient medical scribe market.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
About
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.